In mice, mutant BRAF-induced ERK activation is cancer stage-dependent with significantly higher levels of phosphorylated ERK in high-grade dysplasia and carcinoma (Rad et al., 2013), suggesting that different tumor stages may require different levels of p-ERK. The gene discussed is BRAF; the disease is cancer.